Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.2
(7.61%)
SEK 0.2
(7.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 357.62 Million SEK | 54.27% |
| 2022 | 210.27 Million SEK | 9.56% |
| 2021 | 191.93 Million SEK | -16.94% |
| 2020 | 231.07 Million SEK | 64.71% |
| 2019 | 140.28 Million SEK | 30.48% |
| 2018 | 107.51 Million SEK | 122.07% |
| 2017 | 48.41 Million SEK | 67.11% |
| 2016 | 28.97 Million SEK | 224.27% |
| 2015 | 8.93 Million SEK | 229.81% |
| 2014 | 2.7 Million SEK | 17.95% |
| 2013 | 2.29 Million SEK | 297.0% |
| 2012 | 578.54 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 89.49 Million SEK | 2.3% |
| 2024 Q2 | 129.08 Million SEK | 44.24% |
| 2024 Q3 | 82.07 Million SEK | -36.42% |
| 2023 Q3 | 93.86 Million SEK | -6.5% |
| 2023 Q4 | 87.48 Million SEK | -6.8% |
| 2023 Q2 | 100.39 Million SEK | 38.44% |
| 2023 FY | 324.38 Million SEK | 54.27% |
| 2023 Q1 | 72.52 Million SEK | 16.33% |
| 2022 Q2 | 48.03 Million SEK | 9.23% |
| 2022 Q4 | 62.34 Million SEK | 11.47% |
| 2022 FY | 210.27 Million SEK | 9.56% |
| 2022 Q1 | 43.97 Million SEK | -4.26% |
| 2022 Q3 | 55.92 Million SEK | 16.44% |
| 2021 Q2 | 57.45 Million SEK | 13.15% |
| 2021 Q1 | 50.77 Million SEK | -34.83% |
| 2021 FY | 191.93 Million SEK | -16.94% |
| 2021 Q4 | 45.93 Million SEK | 10.06% |
| 2021 Q3 | 41.73 Million SEK | -27.37% |
| 2020 Q2 | 49.55 Million SEK | 6.05% |
| 2020 FY | 231.07 Million SEK | 64.71% |
| 2020 Q4 | 77.92 Million SEK | 44.52% |
| 2020 Q3 | 53.91 Million SEK | 8.8% |
| 2020 Q1 | 46.73 Million SEK | 29.25% |
| 2019 Q2 | 43.98 Million SEK | 54.69% |
| 2019 Q3 | 31.26 Million SEK | -28.93% |
| 2019 Q4 | 36.15 Million SEK | 15.64% |
| 2019 FY | 140.28 Million SEK | 30.48% |
| 2019 Q1 | 28.43 Million SEK | -77.29% |
| 2018 Q3 | -60.31 Million SEK | -282.07% |
| 2018 Q2 | 33.12 Million SEK | 232.0% |
| 2018 Q4 | 125.24 Million SEK | 307.65% |
| 2018 Q1 | 9.97 Million SEK | -51.12% |
| 2018 FY | 107.51 Million SEK | 122.07% |
| 2017 Q4 | 20.41 Million SEK | 138.77% |
| 2017 Q3 | 8.54 Million SEK | -14.23% |
| 2017 Q2 | 9.96 Million SEK | -30.62% |
| 2017 FY | 48.41 Million SEK | 67.11% |
| 2017 Q1 | 14.36 Million SEK | 200.52% |
| 2016 Q2 | 8.09 Million SEK | 31.89% |
| 2016 Q3 | 9.95 Million SEK | 23.01% |
| 2016 Q1 | 6.13 Million SEK | 184.67% |
| 2016 Q4 | 4.77 Million SEK | -52.0% |
| 2016 FY | 28.97 Million SEK | 224.27% |
| 2015 Q2 | 1.4 Million SEK | 17.93% |
| 2015 Q1 | 1.18 Million SEK | -10.5% |
| 2015 FY | 8.93 Million SEK | 229.81% |
| 2015 Q4 | 2.15 Million SEK | -49.03% |
| 2015 Q3 | 4.23 Million SEK | 201.97% |
| 2014 Q3 | 447 Thousand SEK | 0.0% |
| 2014 Q4 | 1.32 Million SEK | 196.92% |
| 2014 FY | 2.7 Million SEK | 17.95% |
| 2013 FY | 2.29 Million SEK | 297.0% |
| 2012 FY | 578.54 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 76.382% |
| Camurus AB (publ) | 1.05 Billion SEK | 66.251% |
| Mendus AB (publ) | 129.13 Million SEK | -176.933% |
| Lipum AB (publ) | 37.3 Million SEK | -858.595% |
| NextCell Pharma AB | -576.01 Thousand SEK | 62185.278% |
| Simris Alg AB (publ) | 38.64 Million SEK | -825.477% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -1162.51% |
| Active Biotech AB (publ) | 44.8 Million SEK | -698.105% |
| Amniotics AB (publ) | 29.07 Million SEK | -1130.129% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -2340.613% |
| BioArctic AB (publ) | 89.62 Million SEK | -299.013% |
| Cantargia AB (publ) | 290.01 Million SEK | -23.311% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -1533.355% |
| CombiGene AB (publ) | 44.14 Million SEK | -710.126% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -150.109% |
| Genovis AB (publ.) | 88.19 Million SEK | -305.482% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -210.779% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -4820.515% |
| Intervacc AB (publ) | 79.78 Million SEK | -348.233% |
| Kancera AB (publ) | 63.07 Million SEK | -466.963% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -6379.851% |
| LIDDS AB (publ) | 27.75 Million SEK | -1188.639% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -4830.011% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -163.128% |
| OncoZenge AB (publ) | 15.9 Million SEK | -2148.494% |
| Saniona AB (publ) | 1.07 Million SEK | -33105.478% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | -11.234% |
| Xintela AB (publ) | 57.31 Million SEK | -523.95% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -96.784% |
| Ziccum AB (publ) | 27.87 Million SEK | -1182.814% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -2080.495% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | -16.455% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -738.86% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -1922.411% |
| Corline Biomedical AB | 30.16 Million SEK | -1085.438% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -516.262% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -329.996% |
| Aptahem AB (publ) | 10.01 Million SEK | -3471.607% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -165.508% |
| Fluicell AB (publ) | 28.61 Million SEK | -1149.687% |
| Biovica International AB (publ) | 133.72 Million SEK | -167.438% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -1707.089% |
| AcouSort AB (publ) | 25.87 Million SEK | -1282.064% |
| Abliva AB (publ) | 27.86 Million SEK | -1183.367% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -84.818% |
| 2cureX AB (publ) | 36.51 Million SEK | -879.306% |
| I-Tech AB | 40.14 Million SEK | -790.762% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 58.389% |
| Cyxone AB (publ) | 28.21 Million SEK | -1167.537% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -226.991% |
| Biosergen AB | 26.8 Million SEK | -1233.966% |
| Nanologica AB (publ) | 69.88 Million SEK | -411.716% |
| SynAct Pharma AB | 224.49 Million SEK | -59.3% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -709.541% |
| BioInvent International AB (publ) | 441.4 Million SEK | 18.98% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -1392.941% |
| Alzinova AB (publ) | 36.39 Million SEK | -882.589% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -23.426% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -4452.072% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -222.433% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -2332.81% |